PRODUCT INFORMATION

Fevipiprant

Item No. 20263

CAS Registry No.:	872365-14-5
Formal Name:	2-methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl] methyl]-1 H -pyrrolo[2,3b] pyridine-3-acetic acid
Synonyms:	NVP-QAW039, QAW039
MF:	$C_{19}H_{17}F_3N_2O_4S$
FW:	426.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 224, 291 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fevipiprant is supplied as a crystalline solid. A stock solution may be made by dissolving the fevipiprant in the solvent of choice, which should be purged with an inert gas. Fevipiprant is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of fevipiprant in ethanol is approximately 1 mg/ml and approximately 10 mg/ml in DMSO and DMF.

Fevipiprant is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, fevipiprant should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Fevipiprant has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Fevipiprant is a DP_2/$CRTH_2$ antagonist (K_i = 1.05 nM).[1] It reduces shape change of eosinophils induced by prostaglandin D_2 (PGD_2; Item No. 12010) with IC_{50} values of 0.4 and 0.44 nM for isolated human eosinophils and human whole blood, respectively. Fevipiprant inhibits PGD_2-induced release of IL-5 and IL-13 in isolated human $CD4^+$ Th2 cells (IC_{50}s = 2.56 and 1.4 nM, respectively). It reduces the number of eosinophils in bronchoalveolar lavage fluid (BALF) in a mouse model of asthma (ED_{50} = ~1 mg/kg).[2]

References

1. Sykes, D. A., Bradley, M. E., Riddy, D. M., *et al.* Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy. *Mol. Pharmacol.* **89(5)**, 593-605 (2016).
2. Sandham, D., Asano, K., Barker, L., *et al.* Fevipiprant, a potent selective prostaglandin D_2 receptor 2 (DP_2) antagonist, dose-dependently inhibits pulmonary inflammation in a mouse model of asthma. *Am. J. Respir. Crit. Care Med.* **197**, A1418 (2018).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM